

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

- 1-15. Canceled.
16. (Currently Amended) A method of treating glial cells damaged from CNS injury, wherein said CNS injury predominantly affects glia, comprising administering to the CNS of a mammal in need thereof, an effective amount of IGF-1.
17. (Currently Amended) The method of Claim [[1]] 16, wherein the CNS injury is an ischemic injury.
18. (Currently Amended) The method of Claim [[1]] 16, wherein the CNS injury is an hypoxic injury.
19. (Currently Amended) The method of Claim [[1]] 16, wherein the CNS injury is an asphyxia injury.
20. (Currently Amended) The method of Claim [[1]] 16, wherein the CNS injury is an injury to the cortex.
21. (Currently Amended) The method of Claim [[1]] 16, wherein the CNS injury is an injury to the dentate gyrus.

22. (Currently Amended) The method of Claim ~~[[1]]~~ 16, wherein the CNS injury is an injury to the hippocampus.
23. (Currently Amended) The method of Claim ~~[[1]]~~ 16, wherein the CNS injury is a traumatic brain injury.
24. (Currently Amended) The method of Claim ~~[[1]]~~ 16, wherein the CNS injury is a chronic injury.
25. (Currently Amended) The method of Claim ~~[[9]]~~ 24, wherein the chronic injury is a degenerative injury.
26. (Currently Amended) The method of Claim ~~[[10]]~~ 25, wherein the degenerative injury is multiple sclerosis.
27. Canceled.
28. (Currently Amended) A method of treating glial cells damaged from CNS injury, wherein said CNS injury predominantly affects glia, comprising administering to the CNS of a mammal in need thereof, an effective amount of a biological analog of IGF-1, wherein said analog is selected from the group consisting of naturally-occurring analogs, IGF-2, and des 1-3 IGF-1.

29. (Currently Amended) The method of Claim [[13]] 28, wherein the CNS injury is an ischemic injury.
30. (Currently Amended) The method of Claim [[13]] 28, wherein the CNS injury is an hypoxic injury.
31. (Currently Amended) The method of Claim [[13]] 28, wherein the CNS injury is an asphyxia injury.
32. (Currently Amended) The method of Claim [[13]] 28, wherein the CNS injury is an injury to the cortex.
33. (Currently Amended) The method of Claim [[13]] 28, wherein the CNS injury is an injury to the dentate gyrus.
34. (Currently Amended) The method of Claim [[13]] 28, wherein the CNS injury is an injury to the hippocampus.
35. (Currently Amended) The method of Claim [[13]] 28, wherein the CNS injury is a traumatic brain injury.
36. (Currently Amended) The method of Claim [[13]] 28, wherein the CNS injury is a chronic injury.

37. (Currently Amended) The method of Claim ~~[[21]]~~ 36, wherein the chronic injury is a degenerative injury.

38. (Currently Amended) The method of Claim ~~[[22]]~~ 37, wherein the degenerative injury is multiple sclerosis.

39-63. Canceled.

64. (New) A method for treating non-cholinergic cells damaged from CNS injury, comprising administering to the CNS of a mammal in need thereof, an effective amount of IGF-1, wherein the CNS injury is an injury to the hippocampus.

65. (New) A method of treating non-cholinergic cells damaged from CNS injury, comprising administering to the CNS of a mammal in need thereof, an effective amount of a biological analog of IGF-1, wherein the CNS injury is an injury to the hippocampus and further wherein said analog is selected from the group consisting of naturally-occurring analogs, IGF-2, and des 1-3 IGF-1.